Tag: 2b3
ABIONYX Pharma successfully passed the pre-IND meeting with the FDA for a phase 2b/3 clinical study evaluating CER-001 in the treatment of patients with sepsis – 06/13/2024 at 7:30 p.m.
• Based on promising data from its Phase 2a study and a successful meeting with the Food and Drug Administration (FDA), ABIONYX Pharma will file an IND application in the…